B. Riley lowered the firm’s price target on Stereotaxis to $4 from $4.50 and keeps a Buy rating on the shares post the Q3 report. The analyst says the company’s pipeline continues to develop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STXS:
- Stereotaxis Reports 2023 Third Quarter Financial Results
- Stereotaxis reports Q3 EPS (7c), consensus (6c)
- STXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
- Abbott, Stereotaxis report patients treated with integrated tech in the U.S.
